Groupama Asset Managment Increases Position in Boston Scientific Co. (NYSE:BSX)

Groupama Asset Managment grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 20.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,143,931 shares of the medical equipment provider’s stock after acquiring an additional 191,887 shares during the period. Boston Scientific makes up approximately 0.8% of Groupama Asset Managment’s portfolio, making the stock its 25th largest holding. Groupama Asset Managment’s holdings in Boston Scientific were worth $102,588,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. May Hill Capital LLC bought a new position in Boston Scientific during the 4th quarter valued at approximately $5,421,000. Geode Capital Management LLC increased its holdings in shares of Boston Scientific by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider’s stock valued at $2,729,371,000 after acquiring an additional 1,041,329 shares in the last quarter. Nemes Rush Group LLC increased its holdings in shares of Boston Scientific by 312.3% during the fourth quarter. Nemes Rush Group LLC now owns 635 shares of the medical equipment provider’s stock valued at $57,000 after acquiring an additional 481 shares in the last quarter. HighPoint Advisor Group LLC raised its position in shares of Boston Scientific by 9.0% in the 4th quarter. HighPoint Advisor Group LLC now owns 20,429 shares of the medical equipment provider’s stock worth $1,825,000 after purchasing an additional 1,683 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Boston Scientific by 5.3% in the 4th quarter. Franklin Resources Inc. now owns 16,539,488 shares of the medical equipment provider’s stock worth $1,477,307,000 after purchasing an additional 832,386 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the transaction, the executive vice president now owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Daniel J. Brennan sold 67,333 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the transaction, the chief financial officer now owns 225,808 shares in the company, valued at $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 137,302 shares of company stock worth $14,319,269 over the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Trading Up 1.6 %

NYSE:BSX opened at $100.95 on Tuesday. Boston Scientific Co. has a one year low of $66.80 and a one year high of $107.17. The business has a fifty day moving average price of $102.20 and a 200-day moving average price of $93.30. The firm has a market capitalization of $149.30 billion, a price-to-earnings ratio of 80.76, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Sell-side analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Analyst Ratings Changes

BSX has been the subject of several recent analyst reports. Stifel Nicolaus lifted their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Raymond James boosted their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. UBS Group upped their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Piper Sandler lifted their target price on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Finally, Barclays upped their price target on Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.